Investors

Financial reports and presentations

12 August 2020

VACCIBODY AND NEKTAR THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1/2A STUDY ARM EVALUATING VB10.NEO IN COMBINATION WITH BEMPEGALDESLEUKIN

First patient dosed in VB N-01 study arm with VB10.NEO plus Bempegaldesleukin (NKTR-214)

Download
Warning: Undefined array key "HTTP_REFERER" in /var/www/0/351003/www/wp-content/themes/nykode-understrap-child/loop-templates/content-single-financial.php on line 67

Go back